OXIS International, Inc. (OXIS) is a biopharmaceutical/nutraceutical company engaged in the development of research diagnostics, nutraceutical and therapeutic products, which include technologies applicable to conditions and/or diseases associated with oxidative stress. The Company is structured into two wholly owned subsidiaries: OXIS Health Products, Inc., which carries out the Company's commercial health products business that markets research and commercial diagnostic assays and fine chemicals to research and clinical laboratories and other customers, and OXIS Therapeutics, Inc., which carries out the Company's pharmaceutical and nutraceutical discovery and research business that is focused on new drugs and compounds to treat diseases associated with tissue damage from free radicals and reactive oxygen species.